Search by Drug Name or NDC
NDC 00093-1106-16 Teriparatide 250 ug/mL Details
Teriparatide 250 ug/mL
Teriparatide is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Teva Pharmaceuticals USA, Inc.. The primary component is TERIPARATIDE ACETATE.
MedlinePlus Drug Summary
Teriparatide injection is used to treat osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause ('change in life,' end of menstrual periods), who are at high risk of fractures (broken bones), and cannot use other osteoporosis treatments. It is also used to increase bone mass in men with certain types of osteoporosis who are at high risk for having broken bones (fractures), and who cannot use other osteoporosis treatments. Teriparatide injection is also used to treat osteoporosis in men and women who are taking corticosteroids (a type of medication that may cause osteoporosis in some patients) who are at high risk of fractures (broken bones), and cannot use other osteoporosis treatments. Teriparatide injection contains a synthetic form of natural human hormone called parathyroid hormone (PTH). It works by causing the body to build new bone and by increasing bone strength and density (thickness).
Related Packages: 00093-1106-16Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Teriparatide Injection
Product Information
| NDC | 00093-1106 |
|---|---|
| Product ID | 0093-1106_45bf9004-b62a-467f-b3a0-470dc868fba0 |
| Associated GPIs | |
| GCN Sequence Number | 064481 |
| GCN Sequence Number Description | teriparatide PEN INJCTR 20MCG/DOSE SUBCUT |
| HIC3 | P4B |
| HIC3 Description | BONE FORMATION STIM. AGENTS - PARATHYROID HORMONE |
| GCN | 14404 |
| HICL Sequence Number | 024700 |
| HICL Sequence Number Description | TERIPARATIDE |
| Brand/Generic | Generic |
| Proprietary Name | Teriparatide |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Teriparatide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 250 |
| Active Ingredient Units | ug/mL |
| Substance Name | TERIPARATIDE ACETATE |
| Labeler Name | Teva Pharmaceuticals USA, Inc. |
| Pharmaceutical Class | Parathyroid Hormone Analog [EPC], Parathyroid Hormone [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA208569 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00093-1106-16 (00093110616)
| NDC Package Code | 0093-1106-16 |
|---|---|
| Billing NDC | 00093110616 |
| Package | 1 SYRINGE in 1 CARTON (0093-1106-16) / 2.4 mL in 1 SYRINGE |
| Marketing Start Date | 2023-12-18 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |